(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Israel faces tough choices over haredi draft exemptions, legal expert warns - 2One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- 3NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 4Poland open to German troops to help secure Ukraine ceasefire
- 5Well known Tea Brands for Each Tea Sweetheart
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- CPA Canada appoints eight directors as new governance model takes effect
- Going with Children: Tips for Tranquil Family Get-aways
- Remain Cool and Solid: Top Summer Food sources for 2024
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Freed whale gets stranded again off German coast
- Unpaid caregiving work can feel small and personal, but that doesn’t take away its ethical value
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
